Abstract
Clinically utilized antipsychotic agents share as a common mechanism the ability to antagonize dopamine D2 receptors and it is widely assumed that this activity contributes to their efficacy against the positive symptoms of schizophrenia. The efficacy of currently marketed antipsychotic agents on the negative and cognitive symptoms of this disease, however, is not optimal. One alternate hypothesis to the “dopamine hypothesis” of schizophrenia derives from the observation that antagonists of NMDA receptor activity better mimic the symptomatology of schizophrenia in its entirety than do dopamine agonists. Findings from this line of research have led to the NMDA receptor hypofunction (or glutamate dysfunction) hypothesis of schizophrenia, which complements existing research implicating dopamine dysfunction in the disease. According to the NMDA receptor hypofunction hypothesis, any treatment that enhances NMDA receptor activity may prove useful for the treatment of the complex symptoms that define schizophrenia. This idea is now supported by numerous clinical studies that have reported an efficacious response following treatment with activators of the NMDA receptor co-agonist glycineB site. One area of study, aimed at potentiating the NMDA receptor via activation of the glycineB site is small molecule blockade of the glycine reuptake transporter type 1 (GlyT1). Broadly, these efforts have focused on derivatives of the substrate inhibitor, sarcosine, and non-sarcosine based GlyT1 inhibitors. Accordingly, the following review discusses the development of both sarcosine and non-sarcosine based GlyT1 inhibitors and their current status as putative treatments for schizophrenia and other disorders associated with NMDA receptor hypoactivity
Keywords: NMDA receptor, fluoxetine, Non-sarcosine-Derived GlyT1 Inhibitors, GLYT1 mouse models, rat hippocampal slices
Current Topics in Medicinal Chemistry
Title: Progress in the Preparation and Testing of Glycine Transporter Type-1 (GlyT1) Inhibitors
Volume: 6 Issue: 17
Author(s): Craig W. Lindsley, Scott E. Wolkenberg and Gene G. Kinney
Affiliation:
Keywords: NMDA receptor, fluoxetine, Non-sarcosine-Derived GlyT1 Inhibitors, GLYT1 mouse models, rat hippocampal slices
Abstract: Clinically utilized antipsychotic agents share as a common mechanism the ability to antagonize dopamine D2 receptors and it is widely assumed that this activity contributes to their efficacy against the positive symptoms of schizophrenia. The efficacy of currently marketed antipsychotic agents on the negative and cognitive symptoms of this disease, however, is not optimal. One alternate hypothesis to the “dopamine hypothesis” of schizophrenia derives from the observation that antagonists of NMDA receptor activity better mimic the symptomatology of schizophrenia in its entirety than do dopamine agonists. Findings from this line of research have led to the NMDA receptor hypofunction (or glutamate dysfunction) hypothesis of schizophrenia, which complements existing research implicating dopamine dysfunction in the disease. According to the NMDA receptor hypofunction hypothesis, any treatment that enhances NMDA receptor activity may prove useful for the treatment of the complex symptoms that define schizophrenia. This idea is now supported by numerous clinical studies that have reported an efficacious response following treatment with activators of the NMDA receptor co-agonist glycineB site. One area of study, aimed at potentiating the NMDA receptor via activation of the glycineB site is small molecule blockade of the glycine reuptake transporter type 1 (GlyT1). Broadly, these efforts have focused on derivatives of the substrate inhibitor, sarcosine, and non-sarcosine based GlyT1 inhibitors. Accordingly, the following review discusses the development of both sarcosine and non-sarcosine based GlyT1 inhibitors and their current status as putative treatments for schizophrenia and other disorders associated with NMDA receptor hypoactivity
Export Options
About this article
Cite this article as:
Lindsley W. Craig, Wolkenberg E. Scott and Kinney G. Gene, Progress in the Preparation and Testing of Glycine Transporter Type-1 (GlyT1) Inhibitors, Current Topics in Medicinal Chemistry 2006; 6 (17) . https://dx.doi.org/10.2174/156802606778249784
DOI https://dx.doi.org/10.2174/156802606778249784 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology Nonfatal Suicidal Overdose of Olanzapine in an Adolescent
Current Drug Safety Differentiation Between Osteoporotic and Neoplastic Vertebral Fractures: State of The Art and Future Perspectives
Current Medical Imaging A Mendelian Randomization Study on Infant Length and Type 2 Diabetes Mellitus Risk
Current Gene Therapy Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Clinical Aspects of Melatonin Intervention in Alzheimers Disease Progression
Current Neuropharmacology Old Drugs with New Tricks: Paradigm in Drug Development Pipeline for Alzheimer’s Disease
Central Nervous System Agents in Medicinal Chemistry Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Current Drug Targets Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology Micronutrients at the Interface Between Inflammation and Infection Ascorbic Acid and Calciferol. Part 2: Calciferol and the Significance of Nutrient Supplements
Inflammation & Allergy - Drug Targets (Discontinued) Oxidative Stress and Mitochondrial Impairment After Treatment with Anti-HIV Drugs: Clinical Implications
Current Pharmaceutical Design Nicotine and Tobacco Particulate Self-Administration: Effects of Mecamylamine, SCH23390 and Ketanserin Pretreatment
Current Psychopharmacology Important Contributions of a New Quantitative Preparative Native Continuous Polyacrylamide Gel Electrophoresis (QPNC-PAGE) Procedure for Elucidating Metal Cofactor Metabolisms in Protein-Misfolding Diseases - A Theory
Protein & Peptide Letters Convolutional Neural Network Visualization for Identification of Risk Genes in Bipolar Disorder
Current Molecular Medicine The Relationship Between Diabetes Mellitus, Geriatric Syndromes, Physical Function, and Gait: A Review of the Literature
Current Diabetes Reviews A beta oligomerization A Therapeutic Target for Alzheimers Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Euglycemic Diabetic Ketoacidosis: A Review
Current Diabetes Reviews An Update on Herbal Anti-inflammatory Agents in Periodontal Therapy
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Aquaporins in Sensory and Pain Transmission
Current Neuropharmacology